Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Nondiabetic Patients with Chronic Kidney Disease: A Review of Recent Evidence.

Junhao Lv,Luying Guo,Rending Wang,Jianghua Chen

Kidney diseases (Basel, Switzerland)（2023）

引用 0|浏览8

暂无评分

摘要

Considering the robust data available from DAPA-CKD, EMPA-KIDNEY, and other trials such as EMPEROR-Preserved, DIAMOND that included nondiabetic patients, it may be necessary to update current guidelines to include SGLT2i as a first-line therapy for CKD and reevaluate current CKD therapeutic approaches.

查看译文

关键词

nondiabetic patients,chronic kidney disease,inhibitors,sodium-glucose

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要